Phase II open-label, multicenter, randomized trial of neoadjuvant palbociclib in combination with hormonal therapy and HER2 blockade versus paclitaxel in combination with HER2 blockade for elderly patients with hormone receptor positive/HER2 positive early breast cancer.

Trial Co-Chairs info
Laura Biganzoli, MD, Prato, Italy
Etienne Brain, MD, PhD, Paris, France

Lead Trial Coordinator
Holly Shaw

Trial Coordinator
Meredith Kissel

Data Manager
Susan Fischer

Trial Monitors
Giuseppe Achille, Daniela Celotto, Carmen Comune, Magdalena Sànchez-Hohl, Lionel Nobs, Mariana Pardo Contreras

Statistician 
Svitlana Tyekucheva



IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

IBCSG Coordinating Center, Bern, Switzerland
Phone: +41 31 511 94 00
Fax: +41 31 511 94 01
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Date of Activation
Feb 28, 2018

Targeted Accrual

144

International Breast
Cancer Study Group

Effingerstrasse 40
3008 Bern, Switzerland

Contact
Phone: +41 31 511 94 00
E-mail: ibcsgcc@ibcsg.org

Member Login